Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa
2011

IL-10 Gene Variants and Hepatitis B Treatment Response

Sample size: 52 publication Evidence: moderate

Author Information

Author(s): Wang Shaoyang, Huang Dedong, Sun Shunlai, Ma Weimin, Zhen Qin

Primary Institution: Department of infectious diseases, the Fuzhou General Hospital, Fu Zhou, Fujian Province, China

Hypothesis

Variation in interleukin-10 promoter polymorphism would predict the likelihood of sustained response of chronic hepatitis B to treatment with interferon alfa.

Conclusion

The study found that certain IL-10 gene variants are associated with a better initial response to interferon alfa therapy in chronic hepatitis B patients.

Supporting Evidence

  • The -592A allele and -819T allele were more frequent in sustained responders compared to non-responders.
  • Homozygosity for the -592A/A and -819T/T genotypes was strongly associated with sustained response.
  • The study included a control group of 48 healthy volunteers for comparison.

Takeaway

Some people with chronic hepatitis B have genes that help them respond better to a specific treatment, which can help them get better.

Methodology

The study analyzed IL-10 gene polymorphisms in 52 chronic hepatitis B patients using PCR and compared responders to non-responders.

Potential Biases

Potential selection bias due to the retrospective nature of the study.

Limitations

The study was retrospective and limited to a specific population, which may affect the generalizability of the findings.

Participant Demographics

52 Chinese Han patients, with 28 non-responders and 24 sustained responders, predominantly male.

Statistical Information

P-Value

<0.01

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1743-422X-8-28

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication